Terray Therapeutics focuses on changing the way experimentation and computation work together in small molecule drug discovery. It emphasizes the importance of high-quality data at scale to enhance generative AI applications in the field.

Terray Therapeutics

Terray Therapeutics | 6,432 followers on LinkedIn. Everything small molecule drug discovery should be. | Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation.

Jacob Berlin, PhD

Chief Scientific Officer at Terray Therapeutics

Vanessa Taylor

Biotech Executive | Board Member

Sudha Parasuraman

Ma. Cassanova G.

Interested to learn more about how we built the world's largest experimental chemistry dataset (growing by 500M+ measurements a month), and transformed the way experimentation and computation work together to solve the toughest therapeutic challenges? Join our Chief Platform Officer Craig Schulz at the Future Labs, Automation & Technology conference in San Diego on November 12th!

It's been an amazing month at Terray! We had a great time with Nasdaq celebrating our $120M Series B financing, led by Bedford Ridge Capital and NVentures, NVIDIA ’s venture capital arm! And we announced our strategic collaboration with Odyssey Therapeutics to jointly discover and develop first-in-class transcription factor therapies! Our platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges for patients with high unmet medical need. Learn more about our Series B: Press Release: https://lnkd.in/gcRiJUKd Endpoints News Exclusive: https://lnkd.in/gtieiu2P Learn More about our strategic collaboration with Odyssey Therapeutics : https://lnkd.in/gkaVaEUJ #generativeAI #ML #drugdiscovery #biotech

We are excited to announce our strategic collaboration with Odyssey Therapeutics to jointly discover and develop first-in-class transcription factor therapies! At Terray, our proprietary ultra-miniaturized chemistry platform enables unique generative AI capabilities for the discovery and development of small molecule therapeutics. This approach is a perfect complement for Odyssey’s transcription factor biology expertise. We believe that our discovery capabilities and combined expertise in immunology affords us the opportunity to solve incredibly hard challenges and bring relief to patients. Learn More: https://lnkd.in/gqd4rB62 #generativeAI #ML #drugdiscovery #biotech

I’m excited to be participating in GEN's conference: The State of AI in Drug Discovery. I'm on a panel discussion alongside other leaders in the field discussing “Key considerations for Small Molecule Drug Discovery” on Wednesday October 30th at 11AM! Join 3,000 other participants and register for free: https://lnkd.in/gfARfDBq

Thank you Nasdaq for celebrating our $120M Series B financing, led by Bedford Ridge Capital and NVentures, NVIDIA ’s venture capital arm! Our platform uniquely blends experimentation and computation to identify and optimize novel small molecule solutions to the most complex problems. This financing will allow us to advance our internal programs to the clinic to bring medicines to patients in need. Press Release: https://lnkd.in/gcRiJUKd Endpoints Exclusive: https://lnkd.in/gtieiu2P #generativeAI #ML #drugdiscovery #biotech

We’re thrilled to announce our $120M Series B funding round led by Bedford Ridge Capital and NVentures, NVIDIA ’s venture capital arm. Our platform uniquely blends experimentation and computation to identify and optimize novel small molecule solutions to the most complex problems. This financing will allow us to advance our internal programs to the clinic to bring medicines to patients in need. Press Release: https://lnkd.in/gcRiJUKd Endpoints Exclusive: https://lnkd.in/gtieiu2P #generativeAI , #ML , #drugdiscovery , #biotech

Terray Therapeutics , backed by NVentures, has launched a cutting-edge #generativeAI model called COATI-LDM. This model uses multidisciplinary latent diffusion techniques to design small molecules with specific properties. COATI-LDM represents a significant step forward in inverse design for #drugdiscovery and #pharma applications. Terray Therapeutics exemplifies how NVIDIA DGX Cloud can impact #lifesciences applications. Their COATI-LDM model was trained exclusively on a distributed cluster of A100 GPUs in the NVIDIA DGX Cloud, showcasing the platform's powerful capabilities. The COATI-LDM model offers several key features: ✅Control over multiple properties ✅Generation guided by medicinal chemistry preferences ✅Ability to create similar compounds while optimizing specific molecular properties Read the arXiv preprint to learn more https://nvda.ws/3MgI6GG

NVIDIA Healthcare

We are excited to announce our new preprint "Latent Diffusion for Conditional Generation of Molecules" which describes how Terray's generative tools are redefining molecular design for small molecules, enabling the creation of molecules with precise properties that uniquely accelerate and enhance our drug discovery pipeline. Expanding on the generative capabilities of our chemical foundation model COATI, our new generative model, COATI-LDM, incorporates methods from latent diffusion in other domains to provide a highly flexible and controllable framework for generating property-optimized small molecules -- bringing us one step closer to the paradigm of inverse design, which reverses the conventional design process from predictive design (molecule → properties) to generative engineering (properties → molecule). This advancement uniquely positions us to explore the vast chemical space with maximum efficiency, significantly increasing the probability of identifying the optimal molecule to progress our therapeutic programs. Some highlights include: easy multi-property control, generations guided by medicinal chemistry preference, and the capability to generate structurally similar compounds from a starting point while also optimizing desired molecular properties. Learn more: https://lnkd.in/g7BgRBKT #generativeAI , #ML , #drugdiscovery , #biotech

Thank you to Steve Lohr and The New York Times for featuring Terray Therapeutics. We’re proud to be changing the way computation and experimentation work together to generate the kind of data needed to deliver on the promise of A.I. in drug discovery to solve the toughest therapeutic challenges. As our CEO, Jacob Berlin, PhD said: “Once you have the right kind of data, the A.I. can work and get really, really good.” That is our data, and it's all pointed at a “once-in-a-century opportunity" for the pharmaceutical industry to deliver for patients in need. Thank you to our extraordinary team, our partners at Bristol Myers Squibb and Calico Life Sciences , our collaborators at NVIDIA , and all of our amazing investors including Madrona , Digitalis Ventures , Two Sigma Ventures , and KdT Ventures . The best is ahead. Read more: https://lnkd.in/eMtyFdNQ #generativeAI #biotech #ML #drugdiscovery

How will machine learning impact the future of drug development? What are the biggest challenges and opportunities in combining computational and experimental methods in this field? Machine learning is revolutionizing drug development by predicting protein properties and enabling the design of targeted and diverse molecules. Through chip-based experiments and computational modeling, researchers can generate vast amounts of data to optimize molecules for specific therapeutic effects. This scalable and iterative approach reduces clinical development risks by selecting molecules with higher affinity, potency, and selectivity. By combining computational and experimental methods, scientists are accelerating the discovery and optimization of new drugs, leading to more effective and efficient treatments. Check out our full session from the 2024 #MontySummit on biopharma's AI revolution with D.A. Wallach ( Time BioVentures ), Jacob Berlin, PhD ( Terray Therapeutics ), and Michael Nally ( Flagship Pioneering ). #MachineLearning #DrugDevelopment #Biotech #Innovation #Healthcare #AI #biopharma https://lnkd.in/gqQ82qMv

TERR

COM:TERRAYTX

Terray Therapeutics